溶性葡萄糖蛋白VI预测腹腔大动脉动脉瘤的生长率,并且是一个新的治疗点
Tyler W Benson1, Mindy M Pike2,3, Anthony Spuzzillo1,4
1Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH.
Blood
|June 20, 2024
概括
血小板糖蛋白VI (GPVI) 在腹腔大动脉动脉瘤 (AAA) 中升高,预测诊断和生长. 针对GPVI可能为低出血风险的AAA提供新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 血液学 血液学 血液学
- 血管生物学 血管生物学
背景情况:
- 腹腔大动脉瘤 (AAA) 经常出现内血栓 (ILT).
- 血小板激活在AAA相关的ILT病原发生中的作用尚不清楚.
- 血小板在血液静止和血栓形成中起着至关重要的作用.
研究的目的:
- 调查血小板激活在AAA病变发生中的作用.
- 确定AAA的潜在诊断标记和治疗点.
主要方法:
- ILT,动脉瘤壁和健康的大动脉的RNA测序.
- 流细胞计测试以评估血小板表面GPVI.
- 在患者队列中测量可溶性GPVI (sGPVI).
- 在小鼠AAA模型中使用抗GPVI抗体的体内研究.
主要成果:
- 与血小板相关的转录在AAA ILT中显著丰富.
- 葡萄糖蛋白VI (GPVI) 在AAA ILT中含量很高,并且在AAA患者的血小板上增加.
- 可溶性GPVI (sGPVI) 水平预测了AAA诊断和生长速度.
- 在小鼠模型中,抗GPVI抗体治疗减弱了AAA的进展.
结论:
- sGPVI是AAA诊断和生长的预测生物标志物.
- GPVI是AAA的潜在治疗点,出血并发症风险较低.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...


